FeesSafety
Pluang+

Z Squared adds CTO Jeffery Harris to Board to strengthen AI infrastructure site and capital decisions.

Company Fundamentals
04 Nov 2026, 15:30 WIB
PRNewsWire
View Source
Bullish
Z Squared adds CTO Jeffery Harris to Board to strengthen AI infrastructure site and capital decisions.

Z Squared Inc. has appointed its Chief Technology Officer, Jeffery Harris, to its Board of Directors to enhance oversight of its AI infrastructure strategy. Harris brings deep expertise in power, cooling, and high-density computing critical for converting grid-connected power sites into AI-ready capacity. This move aligns with Z Squared's goal of reaching 100 MW of AI infrastructure across multiple U.S. sites by ensuring technical judgment directly influences site selection and capital deployment. Harris will continue as CTO and serve on the Board without additional compensation, emphasizing the company's disciplined approach to capital investment based on signed contracts rather than forecasts.

Z Squared Inc. appoints Jeffery Harris to its Board of Directors. For readers following the Technology sector, here is Pluang's market snapshot as of Nov 04, 2026 20:01 WIB: out of 150 priced US stocks, 77 rose and 66 fell. Notable movers include CDW Corp. at USD 161.42 (+7.78%), VNET Group Inc at USD 3.18 (+6.71%), and Core Scientific Inc at USD 13.30 (-6.60%) with 100% buy order activity on Pluang.

More News

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...

Market News
Bearish
26 minutes ago
Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...

Company Fundamentals
Bullish
26 minutes ago
ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...

Market News
Bullish
26 minutes ago
New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...

Others
Bullish
26 minutes ago
Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...

Market News
Bullish
26 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App